Encapsulation of the HSP-90 Chaperone Inhibitor 17-AAG in Stable Liposome Allow Increasing the Therapeutic Index as Assessed, in vitro, on Leishmania (L) amazonensis Amastigotes-Hosted in Mouse CBA Macrophages

The current long-term treatment for leishmaniasis causes severe side effects and resistance in some cases. An evaluation of the anti-leishmanial potential of an HSP90-inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), demonstrated its potent effect against Leishmania spp. in vitro and in vi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Antonio Luis de Oliveira Almeida Petersen, Thiers A. Campos, Diana Angélica dos Santos Dantas, Juliana de Souza Rebouças, Juliana Cruz da Silva, Juliana P. B. de Menezes, Fábio R. Formiga, Janaina V. de Melo, Giovanna Machado, Patrícia S. T. Veras
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2018-08-01
coleção:	Frontiers in Cellular and Infection Microbiology
Assuntos:	17-AAG Tanespimicyn 2-hydroxypropyl-β-cyclodextrin liposome drug delivery systems leishmaniasis
Acesso em linha:	https://www.frontiersin.org/article/10.3389/fcimb.2018.00303/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!